Navigation Links
University of South Florida receives new multimillion award to assess juvenile diabetes treatments
Date:7/31/2008

Tampa, FL (July 31, 2008) -- The National Institutes of Health has awarded $128 million to the University of South Florida research team led by Jeffrey Krischer, PhD, to coordinate worldwide studies on the prevention and treatment of juvenile diabetes. This latest funding, a seven-year award, supports Dr. Krischer's coordination of the NIH network of clinical research centers known as TrialNet.

The award adds to the $169 million received last year by Dr. Krischer, a professor of pediatrics, to coordinate studies examining the causes of juvenile diabetes. That previously funded 10-year NIH study, known as TEDDY (The Environmental Determinants of Diabetes in the Young), is seeking to explain why the incidence of diabetes in the very young has doubled since the 1980s. The $169-million grant was the largest in USF's history.

"Dr. Krischer's new TrialNet grant will catapult USF to the top 50 for NIH funding to medical schools," said Stephen Klasko, MD, MBA, senior vice president for USF Health and dean of the College of Medicine. "Almost every major effort worldwide to eliminate type 1 diabetes for the next generation comes through here."

"Jeff sees connections other people don't see. He uses tools in new ways to solve very complex problems," said Karen Holbrook, PhD, vice president for research and innovation at USF. "It's an extraordinary program that is doing as much as any program today for people around the globe. It is innovative, and it is important."

Type 1 diabetes, also known as juvenile diabetes, is one of the most common and serious long-term diseases in children and adolescents. It is a disease in which the body's immune system attacks the cells that make insulin a hormone that keeps blood sugar levels stable. Its treatment requires a life-long commitment to daily insulin injections and significant lifestyle changes.

TrialNet will screen more than 150,000 children and adults, identifying those with early signs of diabetes to investigate new therapies that may arrest disease progression. Other studies include treatments of newly diagnosed patients to prevent continued loss of insulin production capability. These treatments, if proven successful, may be tested to determine if they can yield new prevention strategies. In addition to heading the data coordinating and technology center for TrialNet, Dr. Krischer chairs one of the major prevention studies within the consortium a clinical trial investigating whether oral insulin can prevent or delay diabetes in a specific group of people at risk for type 1 diabetes.

TEDDY is screening more than 300,000 newborns and following 8,000 for up to 15 years to investigate the role that diet, infections, and other environmental factors may play in the disease process. Dr. Krischer chairs the study itself as well as directing TEDDY's data coordinating center.

Both TrialNet and TEDDY are being carried out on an international stage through clinical sites in the United States, Canada, Europe, Australia and New Zealand

The two projects complement each other, with virtually every major university and medical center conducting type 1 diabetes research now linked to Dr. Krischer's Pediatric Epidemiology Center at USF. The center is pooling the clinical consortiums' efforts to understand the triggers of diabetes and to develop strategies to prevent or improve treatment. Data describing the everyday lives of study participants, results from research laboratories across the globe, and the clinical course of the disease in affected individuals flow into USF on a continual basis.

All that data is analyzed at USF and shared with scientists, clinicians and investigators worldwide with the goal of putting an end to type 1 diabetes, Dr. Krischer said. "This team effort would not be possible without the outstanding group of 50-plus researchers at USF working on these studies. They are recognized world experts in developing new technologies and informatics applied to medicine," he said. "The research in diabetes complements our other projects in rare diseases, many of which are also autoimmune diseases and share a common etiological pathway. The hope is that our efforts can lead to improvements for all those affected."


'/>"/>

Contact: Anne DeLotto Baier
abaier@health.usf.edu
813-974-3300
University of South Florida Health
Source:Eurekalert  

Related medicine news :

1. Georgetown University Medical Center Collaborates with Indivumed to Develop Cancer Research Database
2. ARUP Laboratories and Weber State University Announce Educational Collaboration
3. The Doctors Channel Adds Esteemed Director of Minimally Invasive Urology at Columbia University to Editorial Team
4. Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant
5. InfoLogix Selected by University Medical Center to Deploy Mobile Wireless Asset Tracking Solution
6. The Connecticut Hospice, Inc. Announces the Arrival of Six Nurse Scholars From The Henrietta Szold-Hadassah-Hebrew University School of Nursing
7. Capella University Launches Online PhD Specialization in Nursing Education
8. Nations Fourth Hand Transplant Performed at Jewish Hospital Hand Care Center by Kleinert Kutz and University of Louisville Surgeons
9. University of Cincinnati professor receives Neuroradiology Societys highest honor
10. Temple University Hospital Ranked Among Best in America for Respiratory Disorders by U.S. News & World Report
11. Howard University and CVS/pharmacy Announce Ribbon Cutting for the Howard University Pharmacy Practice Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
University of South Florida receives new multimillion award to assess juvenile diabetes treatments
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology: